Elite Express Holding Inc. (ETS)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is December - November.

Year Ending	TTM	Nov 30, 2024	Nov 30, 2023
Cash & Equivalents	0.17	0.17	0.05
Cash & Cash Equivalents	0.17	0.17	0.05
Cash Growth	-	211.01%	-
Receivables	0.05	0.06	0.1
Other Current Assets	0.3	0.11	0
Total Current Assets	0.52	0.34	0.16
Property, Plant & Equipment	-	0.28	0.56
Goodwill and Intangibles	-	1.21	-
Other Long-Term Assets	-	0	0.01
Total Long-Term Assets	-	1.49	0.57
Total Assets	-	1.83	0.72
Accounts Payable	-	0.02	-
Current Debt	-	0.03	0.23
Other Current Liabilities	0.48	0.3	0.04
Total Current Liabilities	0.48	0.35	0.26
Long-Term Debt	-	-	0.42
Other Long-Term Liabilities	-	0.11	0
Total Long-Term Liabilities	-	0.11	0.42
Total Liabilities	-	0.46	0.68
Total Debt	0.02	0.03	0.65
Debt Growth	-	-95.51%	-
Retained Earnings	-	-0.31	-0.3
Shareholders' Equity	1.47	1.38	0.04
Net Cash (Debt)	0.14	0.14	-0.59
Working Capital	0.04	-0.01	-0.11

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).